These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 6408407)

  • 1. Clinical and pharmacological aspects of (-)-deprenyl treatment in Parkinson's disease.
    Stern GM; Lees AJ; Hardie R; Sandler M
    Mod Probl Pharmacopsychiatry; 1983; 19():215-9. PubMed ID: 6408407
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson's disease.
    Stern GM; Lees AJ; Hardie RJ; Sandler M
    Acta Neurol Scand Suppl; 1983; 95():113-6. PubMed ID: 6428142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties.
    Elsworth JD; Sandler M; Lees AJ; Ward C; Stern GM
    J Neural Transm; 1982; 54(1-2):105-10. PubMed ID: 6809891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease.
    Presthus J; Hajba A
    Acta Neurol Scand Suppl; 1983; 95():127-33. PubMed ID: 6428145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deprenyl and the progression of Parkinson's disease.
    Science; 1990 Jul; 249(4966):303-4. PubMed ID: 2115691
    [No Abstract]   [Full Text] [Related]  

  • 6. Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease.
    Golbe LI; Duvoisin RC
    J Neural Transm Suppl; 1987; 25():123-9. PubMed ID: 3123598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
    Tetrud JW; Langston JW
    J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deprenyl versus placebo in Parkinson disease: a double-blind study.
    Lieberman AN; Gopinathan G; Neophytides A; Foo SH
    N Y State J Med; 1987 Dec; 87(12):646-9. PubMed ID: 3124027
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease.
    Csanda E; Tárczy M
    Acta Neurol Scand Suppl; 1983; 95():117-22. PubMed ID: 6428143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of L-Deprenyl on on-off phenomena in Parkinson's disease.
    Brodersen P; Philbert A; Gulliksen G; Stigård A
    Acta Neurol Scand; 1985 Jun; 71(6):494-7. PubMed ID: 3927650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
    Tetrud JW; Langston JW
    Science; 1989 Aug; 245(4917):519-22. PubMed ID: 2502843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Phenylethylamine and amphetamine in human brain: effects of L-deprenyl in Parkinson's disease [proceedings].
    Reynolds GP; Riederer P; Sandler M
    Biochem Soc Trans; 1979 Feb; 7(1):143-5. PubMed ID: 437259
    [No Abstract]   [Full Text] [Related]  

  • 13. Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial.
    Presthus J; Berstad J; Lien K
    Acta Neurol Scand; 1987 Sep; 76(3):200-3. PubMed ID: 3120487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-deprenyl treatment of on-off phenomena in Parkinson's disease.
    Rinne UK; Siirtola T; Sonninen V
    J Neural Transm; 1978; 43(3-4):253-62. PubMed ID: 745018
    [No Abstract]   [Full Text] [Related]  

  • 15. Deprenyl for the treatment of early Parkinson's disease.
    N Engl J Med; 1990 May; 322(21):1526-8. PubMed ID: 2110624
    [No Abstract]   [Full Text] [Related]  

  • 16. Experiences with L-deprenyl in Parkinsonism.
    Csanda E; Antal J; Antóny M; Csanaky A
    J Neural Transm; 1978; 43(3-4):263-9. PubMed ID: 370348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAO-B-Inhibitor selegiline (R-(-)-deprenyl). A new therapeutic concept in the treatment of Parkinson's disease. Proceedings of the international symposium. Berlin, January 23-25, 1987.
    J Neural Transm Suppl; 1987; 25():1-197. PubMed ID: 3123595
    [No Abstract]   [Full Text] [Related]  

  • 18. Deprenyl as symptomatic therapy in Parkinson's disease.
    Golbe LI
    Clin Neuropharmacol; 1988 Oct; 11(5):387-400. PubMed ID: 3146432
    [No Abstract]   [Full Text] [Related]  

  • 19. Deprenyl (selegiline) in the treatment of Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1983; 95():107-11. PubMed ID: 6428141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration.
    Reynolds GP; Riederer P; Sandler M; Jellinger K; Seemann D
    J Neural Transm; 1978; 43(3-4):271-7. PubMed ID: 745019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.